Galectin Therapeutics Inc. (GALT) Earnings History
Net Loss26 years of earnings data (2000–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Galectin Therapeutics Inc. (GALT) Earnings Overview
As of June 28, 2026, Galectin Therapeutics Inc. (GALT) reported trailing twelve-month net income of -$26M, reflecting +36.8% year-over-year growth. The company earned $-0.40 per diluted share over the past four quarters.
Looking at the long-term picture, GALT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$190,000 in fiscal 2000.
Galectin Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including HALO ($349M net income, 22.7% margin), AKBA (-$21M net income, -2.3% margin), MDGL (-$309M net income, -30.1% margin), GALT has comparable earnings metrics. Compare GALT vs HALO →
GALT Earnings vs Peers
Earnings metrics vs comparable public companies
GALT Historical Earnings Data (2000–2025)
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$31M | +34.5% | -$20M | $-0.48 | - | - |
| 2024 | -$47M | -14.6% | -$42M | $-0.76 | - | - |
| 2023 | -$41M | -5.9% | -$38M | $-0.74 | - | - |
| 2022 | -$39M | -27.0% | -$38M | $-0.65 | - | - |
| 2021 | -$31M | -30.1% | -$30M | $-0.52 | - | - |
| 2020 | -$23M | -76.5% | -$23M | $-0.41 | - | - |
| 2019 | -$13M | +4.4% | -$13M | $-0.39 | - | - |
| 2018 | -$14M | +14.4% | -$14M | $-0.35 | - | - |
| 2017 | -$16M | +24.3% | -$16M | $-0.46 | - | - |
| 2016 | -$21M | -7.0% | -$21M | $-0.73 | - | - |
| 2015 | -$20M | -26.8% | -$20M | $-0.83 | - | - |
| 2014 | -$16M | -30.6% | -$15M | $-0.72 | - | - |
| 2013 | -$12M | -24.9% | -$12M | $-0.72 | - | - |
| 2012 | -$10M | +11.4% | -$10M | $-0.64 | - | - |
| 2011 | -$11M | -93.9% | -$10M | $-0.91 | - | - |
| 2010 | -$6M | +24.6% | -$5M | $-0.60 | - | - |
| 2009 | -$7M | -136.8% | -$6M | $-0.93 | - | - |
| 2008 | -$3M | +66.6% | -$5M | $-0.40 | - | - |
| 2007 | -$9M | -195.4% | -$6M | $-1.45 | - | - |
| 2006 | -$3M | +51.2% | -$7M | $-0.67 | - | - |
| 2005 | -$7M | +8.9% | -$7M | $-1.44 | - | - |
| 2004 | -$7M | -47.3% | -$7M | $-1.67 | - | - |
| 2003 | -$5M | -32.5% | -$5M | $-1.37 | - | - |
| 2002 | -$4M | +7.4% | -$3M | $-1.35 | - | - |
| 2001 | -$4M | -1989.6% | -$2M | $-1.75 | - | - |
| 2000 | $-190,000 | - | $-170,000 | $-0.09 | - | - |
Download Data
Export GALT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
26+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GALT — Frequently Asked Questions
Quick answers to the most common questions about buying GALT stock.
What is GALT earnings per share (EPS)?
GALT trailing twelve-month (TTM) diluted EPS is $-0.40, reflecting +36.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2000 to 2025 is available in the table on this page.
What is Galectin Therapeutics Inc.'s net income?
Galectin Therapeutics Inc. (GALT) trailing twelve-month net income is $-26M as of 2025. Earnings grew +36.8% year-over-year.
Is GALT profitable?
GALT is not currently profitable on a TTM basis, reporting a net loss of $-26M. Net margin is N/A. Investors should monitor for a return to profitability.
What is GALT's earnings growth rate?
GALT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2000 to 2025.
What are GALT's profit margins?
Galectin Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is GALT growing earnings?
Yes, GALT earnings are accelerating — EPS growth of +36.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-26M. Earnings momentum is strengthening.
What was GALT's best earnings year?
Galectin Therapeutics Inc.'s highest annual net income on record is $-190000.00, achieved in fiscal year 2000. Earnings history on this page spans 2000 to 2025 and includes all annual and quarterly figures.
What were GALT's earnings last quarter?
GALT's most recent reported quarter was Q1 2026. Net income was $-5M with diluted EPS of $-0.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.